Industry

VIDEO: Combination of factors may play role in development, progression of GA

Healio Ophthalmology4h ago1 min read

In this video from the Macula Society meeting, Sunir J. Garg, MD, FACS, FASRS, discusses research concerning the development and progression of geographic atrophy.“The hypothesis is ... maybe all geographic atrophy isn’t the same, and maybe different combinations of oxidative risk factors or complement inhibition may play different roles in the lifetime of geographic atrophy progression,” according to Garg, of the retina service at Wills Eye Hospital.Further research into this idea could improve personalized treatment of geographic atrophy, Garg said.

Read full article on Healio Ophthalmology

AI Summary

Quick Take

At the Macula Society meeting, Dr. Sunir J. Garg proposed that geographic atrophy (GA) is a heterogeneous condition driven by varying combinations of oxidative risk factors and complement system activity. This research suggests that the drivers of GA progression may change over a patient's lifetime, moving the field away from a one-size-fits-all view of the disease.

Why It Matters

As the industry adopts the first generation of complement inhibitors for GA, understanding why some patients progress faster than others is critical. Dr. Garg’s hypothesis addresses a major clinical gap: the reality that GA may not be a single disease entity but a complex interplay of different biological pathways. If progression is indeed driven by shifting factors like oxidative stress at one stage and complement dysfunction at another, then treatment strategies must become significantly more personalized to be effective over the long term.

Key Details

Research presented by Sunir J. Garg, MD, of Wills Eye Hospital at the Macula Society meeting.
The hypothesis suggests that GA is not uniform and that different combinations of risk factors play roles at different stages of the disease.
Key drivers identified include oxidative risk factors and complement inhibition pathways.
The ultimate goal of this research is to transition GA management toward personalized treatment protocols based on individual progression drivers.

Practice Implications

Clinicians should monitor GA progression with the understanding that underlying drivers may vary between patients, potentially impacting their response to emerging complement-based therapies. This research underscores the importance of future diagnostic tools that could identify which specific pathway is most active in a patient at a given time.

Who's Affected

Retina SpecialistsOphthalmologistsOptometristsClinical Researchers

What's Next

Further research is required to confirm how these oxidative and complement factors interact over the lifetime of GA progression. Future clinical trials may begin to look for specific biomarkers that allow for the personalized treatment approach Dr. Garg describes.

Evidence StrengthPreliminary

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.